Preconditioning with periodic acceleration (pGz) provides second window of cardioprotection.
OBJECTIVE
Whole body periodic acceleration (pGz) is achieved with a motorized platform that moves the supine body with repetitive, sinusoidal head to foot motion. This increases pulsatile shear stress to the endothelium thereby activating endothelial nitric oxide synthase (eNOS) to produce increased release of nitric oxide (eNO). The current investigation was undertaken to determine whether or not pGz preconditioning can induce second window of protection (SWOP) cardioprotective affects in an in-vivo rat model of myocardial infarction.


METHODS
Rats received 1, 3 or 7 daily pGz treatments of 60 minutes, or no pGz (CONT). Twenty-four hours after the last pGz treatment, ischemia reperfusion injury was produced by ligation of the left coronary artery (LCA) for 30 minutes followed by 90 minutes of reperfusion.


RESULTS
All pGz preconditioned animals survived 90 minutes. Three and 7 days of pGz preconditioning reduced myocardial infarct size by 41 and 38% respectively, with better left ventricular function. Additionally, pGz preconditioning increased eNOS, p-eNOS, Akt and p-Akt, HSP70 and nNOS proteins. L-NAME (NOS inhibitor) or Wortmannin (PI3/Akt inhibitor) 15 minutes prior to LCA ligation abolished pGz's cardioprotective effects.


CONCLUSIONS
pGz preconditioning provides SWOP, with increased survival, infarct size reduction, and improved contractility, in part due to up regulation of HSP70 and the PI3/Akt/eNOS , which last at least 72 hours.
Mount Sinai Medical Center, 4300 Alton Rd., Miami Beach, FL 33140, USA.
Arkady
A
Uryash
Heng
H
Wu
Jorge
J
Bassuk
Paul
P
Kurlansky
Jose A
JA
Adams
D000054:Acceleration; D000818:Animals; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000378:metabolism*; D018840:HSP70 Heat-Shock Proteins / Q000378:metabolism; D019157:Ischemic Preconditioning, Myocardial / Q000379:methods*; D008297:Male; D009200:Myocardial Contraction / Q000502:physiology; D009203:Myocardial Infarction / Q000473:pathology / Q000517:prevention & control*; D015428:Myocardial Reperfusion Injury / Q000503:physiopathology / Q000517:prevention & control*; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013314:Stress, Mechanical; D015996:Survival Rate; D013997:Time Factors
D018840:HSP70 Heat-Shock Proteins; D052250:Nitric Oxide Synthase Type III; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt